Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Systems integration partner

13 May 2005 07:01

Xaar PLC13 May 2005 FOR IMMEDIATE RELEASE 13 May 2005 Xaar plc IMPIKA APPOINTED AS SYSTEMS INTEGRATION PARTNER Xaar plc ("Xaar"), the inkjet printing technology group headquartered inCambridge, and IMPIKA SA ("IMPIKA") of Aubagne, France are pleased to announce ajoint agreement for the provision of integration services for Xaar printheadsand other products. Under the agreement both parties will co-operate to provide complete turnkeysolutions for clients wishing to use Xaar technology for their productionprocesses, to open up new applications and create bespoke solutions. IMPIKA haslong experience with inkjet, including its application to the printing ofplastic and smart cards, packaging, labelling as well as special applicationsfor printing on CDs, glass and metal. Impika is also developing solutions basedon its material jetting technology for microelectronics and biomedicalapplications. Nigel Berry, Deputy CEO of Xaar commented: "I am very pleased to announce thisrelationship with IMPIKA. We previously stated our intention to partner with asmall number of high quality integrators which can offer existing and potentialusers of our technology a complete package of integration skills and bespokeequipment. We have known the team at IMPIKA for some time now and have beenimpressed by their standards and innovation. I look forward to working withthem on future projects." Paul Morgavi, IMPIKA'S CEO said: "Xaar is a great partner for us and we arealready forming strong links with their technical and marketing teams. There isa clear synergy between Xaar and Impika with both parties introducing newmarkets into the joint relationship. Last year we introduced our C9000 productbased on Xaar's Leopard printhead and we are working on various projects foradapting our IPS print engine to the next generation of Xaar printheads, likethe Omnidot and HSS. Full commercial release of these products is anticipatedlater this year or early next year." About Xaar Xaar plc is a market-leading inkjet technology company. It targets the world'sindustrial, commercial and office printing markets. The industrial andcommercial printing markets are targeted by Xaar's own range of inkjet productsin conjunction with partners and other key players in those markets; the officeprinting market is approached through Xaar's strong list of licensees.Additional information about Xaar is available at www.xaar.co.uk. About IMPIKA: Created in March 2003 as a spin-out from Gemplus, IMPIKA is headquartered atAubagne in the south of France. IMPIKA offers high-performance industrialprinting and material jetting solutions using inkjet technology; it currentlyhas 37 employees. IMPIKA designs, develops, implements and markets hardware and softwaresolutions, as well as the required engineering as regards ink and materialjetting, for industrial applications including digital printing,microelectronics and biotechnologies. Additional information about IMPIKA isavailable at www.impika.com. Contacts Xaar plc: 01223-423663Ian Dinwoodie, Chief Executive www.xaar.co.ukNigel Berry, Group Finance Director & Deputy Chief Executive IMPIKA: +33 (0)4 42 62 43 00Paul Morgavi, CEO www.impika.com Bankside Consultants:Steve Liebmann 020-7444-4163 /07802-888159 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.